1. Home
  2. SD vs PRTC Comparison

SD vs PRTC Comparison

Compare SD & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SandRidge Energy Inc.

SD

SandRidge Energy Inc.

HOLD

Current Price

$14.91

Market Cap

432.9M

Sector

Energy

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$16.75

Market Cap

386.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SD
PRTC
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.9M
386.7M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
SD
PRTC
Price
$14.91
$16.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
391.6K
5.1K
Earning Date
11-05-2025
08-28-2025
Dividend Yield
3.15%
N/A
EPS Growth
40.92
N/A
EPS
1.79
0.20
Revenue
$155,930,000.00
$6,391,000.00
Revenue This Year
$31.95
N/A
Revenue Next Year
$16.82
N/A
P/E Ratio
$8.50
$7.86
Revenue Growth
29.68
1265.60
52 Week Low
$8.81
$13.30
52 Week High
$15.56
$23.35

Technical Indicators

Market Signals
Indicator
SD
PRTC
Relative Strength Index (RSI) 66.30 49.77
Support Level $13.70 $16.01
Resistance Level $15.56 $18.05
Average True Range (ATR) 0.43 0.34
MACD 0.02 0.17
Stochastic Oscillator 64.52 49.02

Price Performance

Historical Comparison
SD
PRTC

About SD SandRidge Energy Inc.

SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: